“Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s63. doi:10.25251/skin.5.supp.63.